SchizophreniaPhase 3NCT01914393
Pediatric Open-Label Extension Study
A Phase 3 study testing Lurasidone 20, 40, 60, 80 mg, flexibly dosed in people with Schizophrenia and Autism, run by Sumitomo Pharma America, Inc. at 88 sites in 15 countries.
Trial summary
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326 Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- Schizophrenia, Autism, Bipolar Depression
- What is being tested?
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 702 participants
- Where
- 88 sitesin 15 countries
- Study dates
- 30 Sep 2013to 17 Oct 2018
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' participation in the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.
- Subject has completed Study D1050301 (Visit 9) OR
- Subject has completed Study D1050325 (Visit 9) OR
- Subject has completed Study D1050326 (Visit 8)
- Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidone treatment, and is able to comply with the protocol.
- A reliable informant (eg, parent, legal guardian, or caregiver) must be available to accompany the subject at each visit. For subjects entering from Study D1050325, the reliable caregiver must also oversee the administration of the study drug throughout the study
Show all 11Show fewer
- Females who participate in this study:
- are unable to become pregnant (eg, premenarchal, surgically sterile, etc.) -OR-
- practices true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent to at least 7 days after the last dose of study drug has been taken; -OR-
- are sexually active and willing to use a medically effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
- Males must be willing to remain sexually abstinent (consistent with lifestyle) or use an effective method of birth control (eg, male using condom and female using condom, diaphragm, contraceptive sponge, spermicide, contraceptive pill, or intrauterine device) from signing informed consent to at least 7 days after the last dose of study drug has been taken.
Who cannot join
- Subject is considered by the investigator to be at imminent risk of suicide.
- Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
Trial locations and contacts
88 sites in 15 countries.
88 sites in 15 countries
United States35 sites
Atlanta Center for Medical Research
Atlanta, Georgia, 30308
Kennedy Krieger Institute
Baltimore, Maryland, 21205
Neurobehavioral medicine Group, LLC
Bloomfield Hills, Michigan, 48302
University of Virginia
Charlottesville, Virginia, 22903
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219
University Hospitals Case Medical Center
Cleveland, Ohio, 44106
Ericksen Research & Development, LLC
Clinton, Utah, 84015
The Ohio State University Nisonger Center
Columbus, Ohio, 43210
Pillar Clinical Research, LLC
Dallas, Texas, 75243
Harmonex Neuroscience Research
Dothan, Alabama, 36303
Diligent Clinical Trials, Inc
Downey, California, 90241
Sarkis Clinical Trials - Parent
Gainesville, Florida, 32607
North Shore/Long Island Jewish PRIME
Glen Oaks, New York, 11004
Neuroscience, Inc.
Herndon, Virginia, 20170
Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340
Lake Charles, Louisiana, 70601
University Of Kentucky
Lexington, Kentucky, 40509
Dr. Jeanette Cueva
Mount Kisco, New York, 10549
Jersey Shore University Medical Center
Neptune City, New Jersey, 07753
Montefiore Medical Center PRIME
New York, New York, 10467
Cutting Edge Research Group
Oklahoma City, Oklahoma, 73116
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, 32801
APG Research, LLC
Orlando, Florida, 32803
Psychiatric Associates
Overland Park, Kansas, 66211
Clinical Research Partners, LLC
Petersburg, Virginia, 23805
Carilion Clinic
Roanoke, Virginia, 24014
Finger Lakes Clinical Research
Rochester, New York, 10618
St. Charles Psychiatric Associates
Saint Charles, Missouri, 63301
University of California San Francisco Medical Center
San Francisco, California, 94143
Medical Research Group of Central Florida
Sanford, Florida, 32771
Neuropsychiatric Research Center of Orange County
Santa Ana, California, 92701
Attalla Consultants, LLC
Smyrna, Georgia, 30080
University of South Florida
St. Petersburg, Florida, 33701
Richmond Behavioral Associates
Staten Island, New York, 10312
University of South Florida Rothman Center of Neuropychiatry
Tampa, Florida, 33613
Family Psychiatry of The Woodlands, P.A.
The Woodlands, Texas, 77381
Russia11 sites
GUZ Lipetsk Regional psychoneurological Hospital #1
Lipetsk, 399313
Closed corporation "Scientific Center of Personalized Psychiatry"
Moscow, 119180
Scientific Center of Personalized Psychiatry
Moscow, 119180
State Healthcare Institution of Nizhniy Novgordo region "Clinical Psychiatric Hospital #1 of City of Nizhniy Novgorod"
Nizhny Novgorod, 603155
SHI "City Psychoneurological dispensary #7 (with Hospital)"
Saint Petersburg, 190005
Center of Recovery Treatment "Pediatric Psychiatry" named after S.S. Mnukhin
Saint Petersburg, 197022
Bekhterev Institute
Saint Petersburg
Regional Clinical Mental Hospital of Saint Sofiya
Saratov, 410060
FSBSI "Scientific Research Institute of Mental Health"
Tomsk, 634014
State Healthcare Institution of Yaroslavl Rgion "Yaroslavl Regional clinical Mental Hospital"
Yaroslavl, 150003
Sverdiovsk Regional Clinical Psychiatric Hospital
Yekaterinburg, 62003
Ukraine10 sites
RPsH #3 Сhildren Dept SHEI Ivano-Frankivsk SMU
Ivano-Frankivsk, 76014
SI Institute of Neurology, Psychiatry and Narcology of NAMSU
Kharkiv, 61068
SI Institute of Children and Adolescents Healthcare of NAMSU
Kharkiv, 61153
TMA Psychiatry in Kyiv Center of NT & Rehabilitation of Psychotic Conditions
Kyiv, 04080
CI Lviv Regional Clinical Psychiatric Hospital
Lviv, 79021
Odesa Regional Psychoneurological Dispensary, Outpatient Dept.
Odesa, 65014
O.F. Maltcev Poltava RCPsH Children Dept Ukrainian Medical Stomatological Academy
Poltava, 36006
CI Kherson Regional Psychiatric Hospital of Kherson RC
Stepanovka, 73488
Ternopil RCCPH Dept of Psychiatry #9 (adolescent)& #8 (pediatric) Ternopil I.Ya. Gorbachevskyi SMU
Ternopil, 46020
Reg. Psych. Hosp.n.a. O.Yuschenko, Dept. #121 VNMI
Vinnitsia, 21018
Mexico6 sites
Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C.
Culiacán, Sinaloa, 80020
Dr. Jessica Rosas Escobar
Durango, 34000
Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
Durango, 34000
Accelerium S. de R.L. de C.V.
Monterrey, 64000
Instituto de Informacion de Investigacion en Salud Mental
Monterrey, 64710
Av Modesto Arreola #917 Ote. Col Centro
Nuevo León, 64000
Bulgaria4 sites
MHC - Ruse, EOOD
Rousse, 7003
UMHAT "Alexandrovska" EAD
Sofia, 1431
MHAT-Targovishte, AD
Targovishte, 7700
DCC "Mladost M" - Varna, OOD
Varna, 9020
Philippines4 sites
Alexian Brothers Health and Wellness Center
Davao City, 8000
West Visayas State University Medical Center
Iloilo City, 5000
National Center for Mental Health
Mandaluyong, 1553
Veterans Memorial Medical Center
Quezon City, 1101
South Korea4 sites
Chonnam National University Hospital
Gwangju, 501-757
Inha University Hospital
Incheon, 400-711
Chonbuk National University Hospital
Jeonju, 561-712
Seoul National University Hospital
Seoul, Gyeonggi-do, 110774
Colombia3 sites
Centro de Investigaciones y Proyectos en Neurociencias CIPNA
Barranquilla
E.S.E. Hospital Mental de Antioquia
Bello, 0000
Centro de Investigaciones del Sistema Nervioso Limitada - Grupo CISNE Ltda
Bogotá, 00000
Romania3 sites
Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
Bucharest, 041914
Spitalul Clinic de Psihiatrie Socola
Iași, 700282
Spitalul Clinic de Urgenta pentru Copii "Louis Turcanu" Timisoara
Timișoara, 300239
Hungary2 sites
Vadaskert Alapitvany a Gyermekek Lelki Egeszsegeert
Budapest, 1021
Bekes Megyei Pandy Kalman Korhaz
Gyula, 57--
Poland2 sites
NZOZ Poradnia Zdrowia Psychicznego
Kobierzyce, 55-040
Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddzial Kliniczmy VI Psychiatrii Mlodziezy
Torun, 87-100
Puerto Rico1 site
Centro de Investigacion Clinica Psiquiatrica
Caguas, 00725
About this study
Official title: A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Being tested
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Keywords
- Schizophrenia, Autism, Lurasidone, Latuda
- Medical subject headings
- Schizophrenia, Autistic Disorder, Bipolar Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lurasidone 20, 40, 60, 80 mg, flexibly dosedDrug
Also called Latuda
Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
| Study group | Role | What they receive |
|---|---|---|
| Lurasidone 20, 40, 60, 80 mg, flexibly dosed | Experimental | Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily Receives: Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosed |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)
The Safety population consists of all subjects who received at least one dose of study drug in this study.
Measured: During 104 Weeks (2-years) treatment period
Secondary outcomes (22)
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
Change from Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score for subjects continued from study D1050301.
PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210 Higher values of PANSS total score represents greater severity of illness.
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Positive Subscale Score
Change from Baseline in PANSS Positive Subscale Score for subjects continued from study D1050301 The Positive scale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness /persecution, and hostility; Positive subscale (range 7-49) is calculated as sum of Items P1 to P7 in the positive subscale Higher values of PANSS sub-scale scores represent greater severity
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Negative Subscale Score
Change from Baseline in PANSS Negative Subscale Score for subjects continued from study D1050301 The Negative scale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; Negative subscale (range 7-49) is calculated as sum of Items N1 to N7 in the negative subscale Higher values of PANSS sub-scale scores represent greater severity of illness.
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS General Psychopathology Subscale Score
Change from Baseline in PANSS General Psychopathology Subscale Score for subjects continued from study D1050301 The General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation; General psychopathology subscale (range 16-112) is calculated as sum of Items G1 to G16 in the general psychopathology subscale Higher values of PANSS sub-scale scores represent greater severity of illness.
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Excitability Subscale Score
Change from Baseline in PANSS Excitability Subscale Score for subjects continued from study D1050301 Subscale of Excitability consists of the following four items from the PANSS: excitement, hostility, uncooperativeness, and poor impulse control. The sum of the four items ranges from 4 to 28 Higher values of PANSS sub-scale scores represent greater severity of illness.
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in the Clinical Global Impression -Severity Score
Change from Baseline in the Clinical Global Impression -Severity Score for subjects continued from study D1050301 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score
Change from Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score for subjects continued from study D1050301 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050301
The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:
% Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score
Change from Baseline in ABC Irritability Subscale Score for subjects continued from study D1050325 The Aberrant Behavior Checklist (ABC) contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Irritability Subscale Score is calculated as summing of items 2, 4, 8, 10, 14, 19, 25, 29, 34, 36, 41, 47, 50, 52, and 57; as a result, ABC irritability subscale score ranges from 0 to 45.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score
Change from Baseline in ABC Lethargy and Social Withdrawal Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Lethargy and Social Withdrawal Subscale Score is calculated as summing of items 3, 5, 12, 16, 20, 23, 26, 30, 32, 37, 40, 42, 43, 53, 55, and 58. ABC Lethargy and Social Withdrawal Subscale Score ranges from 0 to 48.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score
Change from Baseline in ABC Stereotypic Behavior Subscale Score for subjects continued from study D1050325. The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Stereotypic behavior Subscale Score is calculated as summing of 6, 11, 17, 27, 35, 45, and 49 items . ABC Stereotypic behavior Subscale Score ranges from 0 to 21. Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree). To score the ABC, the individual items for each subscale are simply summed to their respective totals. It is inappropriate to compute a "total aberrant score", based on a summation of all 58 items, as the subscales are largely independent. In general, higher values of ABC subscale scores represent greater severity
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score
Change from Baseline in ABC Hyperactivity and Noncompliance Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Hyperactivity and noncompliance Subscale Score is calculated as summing of 1, 7, 13, 15, 18, 21, 24, 28, 31, 38, 39, 44, 48, 51, 54, and 56 items. ABC hyperactivity and noncompliance Subscale Score ranges from 0 to 48.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score
Change from Baseline in ABC Inappropriate Speech Subscale Score for subjects continued from study D1050325 The ABC contains 58 items resolve into five subscales: (1) irritability and agitation (15 items), (2) lethargy and social withdrawal (16 items), (3) stereotypic behavior (7 items), (4) hyperactivity and noncompliance (16 items), and (5) inappropriate speech (4 items). Each item is rated for severity on a 4-point Likert scale ranging from 0 (not at all a problem) to 3 (the problem is severe in degree).
Inappropriate speech Subscale Score is calculated as summing of 9, 22, 33, and 46 items. ABC inappropriate speech Subscale Score ranges from 0 to 12.
In general, higher values of ABC subscale scores represent greater severity of illness. If one or more items are missing, no imputation was performed and the scores of the subscales that include these items was left missing
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinical Global Impression (CGI) - Severity Score
Change from Baseline in Clinical Global Impression (CGI) - Severity Score for subjects continued from study D1050325 The CGI-S is a single value, clinician-rated assessment of illness severity, and 7-point scale with range from 1='Normal, not at all ill' to 7='Among the most extremely ill patients'. A higher score is associated with greater illness severity
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)
Change from Baseline in CY-BOCS for subjects continued from study D1050325 CY-BOCS used in the study is a modification of the Yale-Brown Obsessive Compulsive Scale and contains total 7 items for compulsion. "Obsessions" section was removed as it is difficult to obtain valid information given typical language/cognitive delays in the population. Each item of the compulsive scale ranges from 0 to 4. At this time, item 1b ("compulsion-free interval") and item 6 ("peculiarity of the behavior") are not being used in the scoring. Item 7 is a rating for reliability, ranging from 0 (excellent) to 3 (poor). It reflects the interview's judgment regarding the confidence in the data collected hence it is not counted in the CY-BOCS total score. The CY-BOCS compulsion total score is the sums of item 1-5. As a result, the CY-BOCS compulsion total score may range from 0 to 20. In general, higher values of CY-BOCS scores represent greater severity of illness
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score
Change from Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score for subjects continued from study D1050325 The CGSQ is comprised of total 21 items. Each item is rated on a 5-point Likert-type scale (1 (not at all a problem) to 5 (very much a problem)) and is grouped into three subscales: objective strain, subjective externalized strain, and subjective internalized strain. The 3 subscale scores are calculated as the averages of the corresponding individual items, which range in severity from 1 to 5.
Higher scores on each of these subscale scales indicate greater strain. A global strain score is calculated by summing the three subscales (i.e., objective strain, subjective externalized strain, and subjective internalized strain) to provide an indication of the total impact of the special demands on the family. Global strain scores range from 3 to 15. As with the individual subscales, higher scores indicate greater strain
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score
Change from Baseline in CDRS-R Total Score for subjects continued from study D1050326 CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with depression in childhood. The CDRS-R is administered separately to the patient and to the caregiver; among 17 items, 14 items are based on separate interviews with child and parent, 3 items are based solely on the rater's observation of child (ie, no questions).The 14 items are rated on a 1 (no psychopathology) to 7 (most psychopathology) scale, where a rating of 3 represents mild psychopathology. The 3 items (sleep disturbance, appetite disturbance, listless speech) are rated on a 1 (no pathology) to 5 (most pathology) scale. The CDRS-R total score ranges from 17-113. In general, higher values of CDRS-R total score represent greater severity of illness
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score
Change from Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score for subjects continued from study D1050326 The CGI-BP-S is a three-question clinician-rated assessment of the subject's current illness state (depression, mania, and overall) using a 7-point scale (1(normal, not ill) to 7 (very severely ill)) for each question, where a higher score is associated with greater illness severity.
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score
Change from Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score for subjects continued from study D1050326 The Children's Global Assessment Scale (CGAS) is a numeric scale (1 through 100) used by mental health clinicians to rate the general functioning of children under the age of 18, where 1 represents the most impaired functioning and 100, superior functioning. Each decile (e.g., 1-10, 11-20) has a descriptive header (e.g., "Moderate impairment in functioning in most domains") and examples of behaviors and types of environmental accommodations that might be seen at that level of functioning. Scores above 70 on the CGAS indicate functioning within the range of typically developing children of the same age as the child being rated while scores below 60 indicate a definite clinical case
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
Change from Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score for subjects continued from study D1050326
The Pediatric Q-LES-Q is a 15-item self-report measure of the degree of enjoyment and satisfaction in various areas of daily living, based on the content of the Short From of the Q-LES-Q. Each item is rated on a 5-point scale, ranging from 1 (very poor) to 5 (very good). The first 14 items are the same as the General Activities section of the regular Q-LES-Q form and are used to compute the raw score. The PQ-LES-Q-SF percentage maximum possible score is calculated as follows:
% Max = 100 × (Raw Score - Minimum Score) / (Maximum Score - Minimum Score), where the Minimum Score equals 14 and the Maximum Score equals 70, and the % maximum possible score can range from 0% to 100%. Higher scores indicate better quality of life.
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score
Change from Baseline in PAR Total Score for subjects continued from study D1050326 The PARS is a clinician-rated instrument for assessing over time the severity of anxiety symptoms associated with common DSM-IV anxiety disorders in children ages 6 17 years. The PARS is administered separately to the subject and to the caregiver. The instrument has 2 sections. The first section includes a 50-item symptom checklist, which the clinician rates as present or absent during the past week. The second section is comprised of 7 severity impairment items reflecting the severity/impairment of all symptoms endorsed in Section 1 of the PARS (during the past week). Each question is answered on a 0-5 Likert scale (0 for none, and 1-5 for minimal to extreme) with alternative responses of 8=Not Applicable and 9=Does Not Know. Scores of 8 or 9 are not counted in the summation as per the PARS instructions. The PARS total score over all 7 questions ranges in value from 0 to 35.A higher PARS total score
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score
Change from Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score for subjects continued from study D1050326 The ADHD-RS IV is a validated scale that measures the behaviors of children with ADHD. The ADHD-RS IV consists of 18 items reflecting current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored from a range of 0 (no symptoms) to 3 (severe symptoms) with total scores ranging from 0 to 54. The 18 items may be grouped into two sub-scales: hyperactivity/impulsivity (even number items 2 through 18) and inattentiveness (odd number items 1 through 17), ranging from 0 to 27. A higher ADHD-RS total score and sub-scales scores are associated with greater illness severity
Measured: Open-Label Baseline, Week 28, Week 52, and Week 104
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Aug 2013 (estimated)
- Study start30 Sep 2013
- Primary completion17 Oct 2018
- Study completion17 Oct 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 702 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Lurasidone Medical Director, MD, Study director, Sumitomo Pharma America, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01914393
- Sponsor's protocol ID
- D1050302
- Other IDs
- 2013-001694-24
- Status last verified
- Dec 2019
- First submitted
- 30 Jul 2013
- Last updated
- 19 Dec 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
DelBello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. J Child Adolesc Psychopharmacol. 2021 Sep;31(7):494-503. doi: 10.1089/cap.2021.0040. Epub 2021 Jul 29.
PubMed 34324397
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
- ClinicalTrials.gov ID
- NCT01914393
- Acronym / sponsor ID
- D1050302
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Keywords
- Schizophrenia, Autism, Lurasidone, Latuda
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 702 participants (actual)
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry (pharma, biotech, devices)
- Study start
- 30 Sep 2013 (actual)
- Primary completion
- 17 Oct 2018 (actual)
- Study completion
- 17 Oct 2018 (actual)
- First posted
- 2 Aug 2013 (estimated)
- Results
- Posted 19 Dec 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Lurasidone 20, 40, 60, 80 mg, flexibly dosed | Experimental | Drug: Lurasidone 20, 40, 60, 80 mg, flexibly dosedLurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (11 listed)
- Written informed consent from parent(s) or legal guardian(s) with sufficient intellectual capacity to understand the study and support subjects' participation in the study procedures must be obtained for subjects who are not emancipated. In accordance with Institutional Review Board (IRB) or Independent Ethics Committee (IEC) requirements, the subject will complete an informed assent when developmentally appropriate, to participate in the study before conduct of any study-specific procedures.
- Subject has completed Study D1050301 (Visit 9) OR
- Subject has completed Study D1050325 (Visit 9) OR
- Subject has completed Study D1050326 (Visit 8)
- Subject is judged by the investigator to be appropriate for participation in a 104-week clinical trial in an outpatient setting involving open-label lurasidone treatment, and is able to comply with the protocol.
Key exclusion criteria (2 listed)
- Subject is considered by the investigator to be at imminent risk of suicide.
- Exhibits evidence of moderate or severe extrapyramidal symptoms, dystonia, tardive dyskinesia, or any other moderate or severe movement disorder. Severity to be determined by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lurasidone 20, 40, 60, 80 mg, flexibly dosedAlso: LatudaLurasidone 20, 40, 60, 80 mg once daily, flexibly dosed | Drug | Lurasidone 20, 40, 60, 80 mg, flexibly dosed |
Primary outcome
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)
Time frame: During 104 Weeks (2-years) treatment period
The Safety population consists of all subjects who received at least one dose of study drug in this study.
22 secondary outcomes
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Positive Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Negative Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS General Psychopathology Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in PANSS Excitability Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in the Clinical Global Impression -Severity Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinician-Rated Children's Global Assessment Score (CGAS) Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Irritability Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Lethargy and Social Withdrawal Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Stereotypic Behavior Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Hyperactivity and Noncompliance Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Aberrant Behavior Checklist (ABC) Inappropriate Speech Subscale Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinical Global Impression (CGI) - Severity Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Children's Yale-Brown Obsessive Compulsive Score (CY-BOCS)
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Caregiver Strain Questionnaire (CGSQ) Global Strain Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Children's Depression Rating Scale, Revised (CDRS-R) Total Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinical Global Impression Bipolar Version (CGI-BP-S) Depression Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Clinician-rated Children's Global Assessment Scale (CGAS) Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Percentage Maximum Possible Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Pediatric Anxiety Rating Scale (PAR) Total Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Change From Baseline in Attention-Deficity/Hyperactivity Disorder Rating Scale (ADHD-RS) Total Score
Time frame: Open-Label Baseline, Week 28, Week 52, and Week 104
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 34324397DelBello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression. J Child Adolesc Psychopharmacol. 2021 Sep;31(7):494-503. doi: 10.1089/cap.2021.0040. Epub 2021 Jul 29.
Related trials for Schizophrenia
Not yet recruitingPhase 1
Phase I Trial of HHK101 in Patients With Schizophrenia
Schizophrenia
Not yet recruiting
Integrated Psychoeducation Program for Internalized Stigma in Schizophrenia
Schizophrenia, Schizoaffective Disorder
Not yet recruiting
Non-Invasive Vagus Nerve Stimulation as a Probe to Map Functional Connectivity in Schizophrenia Using Functional Magnetic Resonance Imaging
Schizophrenia Spectrum Disorders
Not yet recruiting
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
Suicide, Mental Health Stigma
RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lurasidone Medical Director, MD study director
Sumitomo Pharma America, Inc.
88 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Lurasidone 20, 40, 60, 80 mg, flexibly dosed in people with Schizophrenia and Autism, run by Sumitomo Pharma America, Inc. at 88 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 88 sites in United States, Russia, Ukraine, Mexico, Bulgaria and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Dec 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs) (time frame: During 104 Weeks (2-years) treatment period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01914393, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2019.